ROCKWELL MEDICAL, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
ROCKWELL MEDICAL, INC. (RMTI) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $500.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-13
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $500.00K.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.30M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.30M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.30M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |